TheraRadar
← Back
Data updated: Mar 29, 2026

YUNG SHIN PHARM

Infectious DiseaseDermatologyGastroenterology
Generics

YUNG SHIN PHARM is a generic drug manufacturer focused on Infectious Disease, Dermatology, Gastroenterology.

2004
Since
11
Drugs
-
Trials
63
Approved (2yr)

Key Drugs

DICLOFENAC SODIUM AND MISOPROSTOL
diclofenac sodium
Immunology
COX-1 4 indications · 2012

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

AZITHROMYCIN 2025-09-23
Labeling
ELETRIPTAN HYDROBROMIDE 2025-07-07
CEPHALEXIN 2025-05-07
Labeling
CEPHALEXIN 2025-05-07
Labeling
CEPHALEXIN 2025-05-07
Labeling
CEPHALEXIN 2025-05-07
Labeling
DICLOFENAC SODIUM AND MISOPROSTOL 2025-03-31
Labeling
DICLOFENAC SODIUM AND MISOPROSTOL 2025-03-31
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 27%
2 drugs Phase 1: 2
Dermatology 24%
2 drugs
Gastroenterology 24%
2 drugs
Neurology 14%
1 drugs Phase 1: 1
Immunology 12%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Infectious Disease, Dermatology, Immunology, Gastroenterology
Bristol-Myers Squibb big-pharma
Immunology, Gastroenterology, Infectious Disease, Neurology
AbbVie big-pharma
Immunology, Neurology, Infectious Disease
PAI HOLDINGS PHARM big-pharma
Dermatology, Infectious Disease, Neurology, Immunology
GSK big-pharma
Infectious Disease, Immunology, Neurology